Skip to content

Manual Dexterity Control After Cerebellar Stimulation

Assessment of Cerebellar Stimulation Effect on Motor Learning in Ageing Population and Stroke Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03092570
Acronym
MADECCS
Enrollment
60
Registered
2017-03-28
Start date
2017-06-12
Completion date
2019-06-30
Last updated
2017-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Keywords

Motor learning, stroke, tDCS, upper limb

Brief summary

This study will assess the putative advantages of cerebellar stimulation on motor learning abilities of stroke patients. In order to have a control group to refer to, the effect of cerebellar stimulation on healthy young and old participants will also be assessed.

Detailed description

Cerebrovascular accidents (CVA) are the first cause of acquired disability in France. Despite rehabilitation interventions, a great proportion of patients suffers from motor disability in the upper limb. Recently, several studies have shown that post CVA patients exhibit great neural plasticity as a direct consequence of their condition. Interestingly, the transcranial direct current stimulation (tDCS) is a non-invasive electro stimulation technique that allows for a modulation of cerebral activity. It has been shown that when applied to the cerebellum, tDCS increases learning performances of healthy subjects. Yet, motor rehabilitation after a CVA highly relies on motor (re)learning. The cerebellar tDCS thus appear as a promising method to enhance the performance of post-CVA motor learning and consequently the benefits of post-CVA rehabilitation. The current study aims to promote the post CVA neural plasticity by using the tDCS in order to enhance motor learning of the upper limb.

Interventions

DEVICEWith stimulation

ramp stimulation from 0 to 2 mA followed by 20 minutes of stimulation at 2mA while practicing during 3 of the 4 sessions

ramp stimulation from 0 to 2 mA followed by 30 sec of stimulation at 2mA.

Sponsors

Centre Hospitalier St Anne
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Right-handed * Affiliated to the French health insurance or similar organisation * Signed informed consent * Clinical examination For Post-AVC patients : * at least 18 years old * completed the Moberg Pick-up test with a minimum score of 20 secondes For Young healthy group * 18 = or \> years = or \<30 For Older healthy group * 50 \> or = years = or \< 80

Exclusion criteria

* Metallic implant in the head * Pacemaker, or other electronic implanted devices * Other central neurological disease * Pregnancy, breast feeding * Previous history of neurosurgery or seizures or 1st degree relative with history of seizures * History of medical neurological or psychiatric disorders * Participation to another study using cerebral stimulation * History of bi-polar or recurring depressive disorders * Planned carotid revascularization, severe caridac disease * Kidney failure (transaminase \> 2 times normal value) * Other invalidating condition or deficiency interfering with the study For Post-AVC patients : * NIHSS score \> 20 * Cerebellar ischemic CVA

Design outcomes

Primary

MeasureTime frameDescription
Force controlDay 1Measurement in Newton of the force applied by each finger.
OverflowDay 1Measurement in ms of the involuntary finger movements.

Secondary

MeasureTime frameDescription
Moberg Pick-up TestDay 1Assessment of the functionality of the hand. One score will be given at the end of the test.
Action Research Arm TestDay 1Assessment of the upper limb mobility. One score will be given at the end of the test
Finger time releaseDay 1Time needed to release the finger force when needed (in ms).

Countries

France

Contacts

Primary ContactMarion Verneau, PhD
mverneau@gmail.com+33140788663
Backup ContactMarie GODARD
marie.godard@aphp.fr00 33 1 45 65 77 28

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026